Cryo-Cell International, Inc. (CCEL) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Medical - Care Facilities Branche. Der Hauptsitz des Unternehmens ist in Oldsmar, FL, United States. Der aktuelle CEO ist David I. Portnoy.
CCEL hat IPO-Datum 1994-04-04, 82 Vollzeitbeschäftigte, gelistet an der NYSE, eine Marktkapitalisierung von $29.56M.
Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, and auto-immune diseases. The company also manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It stores approximately 500,000 cord blood and cord tissue stem cells worldwide. The company markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. Cryo-Cell International, Inc. was incorporated in 1989 and is headquartered in Oldsmar, Florida.
